01.12.2022 | Case report
Bendamustine/polatuzumab-vedotin/rituximab
Lack of efficacy following an off-label use: case report
Erschienen in: Reactions Weekly | Ausgabe 1/2022
Einloggen, um Zugang zu erhaltenExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event